Sign Up to like & get
recommendations!
0
Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-0664
Abstract: Purpose: Patients with triple-negative breast cancer (TNBC) with homologous recombination deficient tumors achieve significantly higher pathologic complete response (pCR) rates when treated with neoadjuvant platinum-based therapy. Tumor-infiltrating lymphocytes (TIL) are prognostic and predictive of chemotherapy…
read more here.
Keywords:
status;
hrd;
cancer;
hrd status ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-a074
Abstract: Background: The combination of cediranib (ced) and olaparib (olap) improves progression-free survival and overall response rates (ORR) in women with recurrent plat sensitive high-grade serous (HGS) ovarian cancer compared to olap alone. In this Phase…
read more here.
Keywords:
status;
plat sensitive;
hrd;
cancer ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.ovarian25-a019
Abstract: The introduction of poly (ADP-ribose) polymerase (PARP) inhibitors has transformed the therapeutic landscape for patients with epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC), particularly those harboring BRCA1/2 mutations or tumors characterized by homologous…
read more here.
Keywords:
test;
ovarian cancer;
hrd status;
status ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2021 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs20-gs3-05
Abstract: Introduction/Aims: DDIR signature, HRD, and stromal tumor infiltrating lymphocytes (sTIL) have each been associated with favorable outcomes in early stage TNBC. We assessed the overlap between these markers and created prognostic categories based on their…
read more here.
Keywords:
status;
ddir hrd;
hrd;
cancer ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.5568
Abstract: 5568 Background: Nearly 50% of patients with high grade ovarian cancer (HGOC) harbor a germline or somatic mutation in BRCA1/BRCA2 or have tumors characterized by homologous recombination deficiency (HRD). HRD is associated with response to…
read more here.
Keywords:
brca hrd;
hrd status;
hrd;
germline brca ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e17501
Abstract: e17501 Background: In cancer therapy, understanding homologous recombination deficiency (HRD) is paramount, particularly due to its positive association with sensitivity to PARP inhibitor (PARPi) therapy. We propose using a targeted sequencing approach as a cost-effective…
read more here.
Keywords:
targeted panel;
hrd;
using targeted;
hrd status ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.3074
Abstract: 3074 Background: Homologous recombination and repair (HRR) deficiency (HRD) is characterized by genomic instability associated with mutations in BRCA1/2 or other HRR genes. HRD can also be detected by copy number variant (CNV) features, indels,…
read more here.
Keywords:
patients advanced;
hrd status;
status;
breast prostate ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e15165
Abstract: e15165 Background: Ovarian tumors with defects in the homologous recombination (HR) pathway have improved treatment response to DNA-damaging agents. HR deficiency (HRD) status is calculated through biomarker scores like large scale state transitions (LST), telomeric…
read more here.
Keywords:
loh;
tai;
hrd status;
status ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.746571
Abstract: Homologous recombination deficiency (HRD) is an approved predictive biomarker for Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer. However, the proportion of positive HRD in the real world and the relationship between HRD status and…
read more here.
Keywords:
cancer;
hrd status;
hrd;
cancer patients ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2025 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2024.1477759
Abstract: Introduction This study predicted HRD score and status based on intra- and peritumoral radiomics in patients with ovarian cancer (OC) for better guiding the use of PARPi in clinical. Methods A total of 106 and…
read more here.
Keywords:
predicting hrd;
spe;
hrd status;
status ... See more keywords